NovaBridge Biosciences has announced the initiation of a global, randomized Phase 2 clinical study evaluating givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with first-line (1L) metastatic HER2-negative gastric cancer. The Phase 2 trial follows positive Phase 1b results, which demonstrated a 75% objective response rate and a median progression-free survival of 16.9 months. Top line results from the Phase 2 study are expected in 2027, and updated results from the Phase 1b dose expansion study are anticipated in the second half of this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief on February 17, 2026, and is solely responsible for the information contained therein.